<div id="secondary-menu" class="nav-mega-wrapper sub-menu" >
        <nav class="nav-mega" itemscope="itemscope" itemtype="http://schema.org/SiteNavigationElement">
            <a href="#" id="cosentyx-logo">
                <img itemprop="logo" class="logo" src="/siteassets/hcp-portal-master/medicines/cosentyx/img/cosentyxlogo.svg" alt="ServiceSphere GB">
            </a>
            <a href="#" class="nav-mega-link " itemprop="name" id="sec-menu0">Home</a>
            <a href="#" class="nav-mega-link " itemprop="name" id="sec-menu1">Early<br>Intervention</a>
            <a href="#" class="nav-mega-link " itemprop="name" id="sec-menu2">Targeting<br>Inflammation</a>
            <a href="#" class="nav-mega-link " itemprop="name" id="sec-menu2">Ankylosing<br>Spondylitis</a>
            <a href="#" class="nav-mega-link " itemprop="name" id="sec-menu2">Psoriatic<br>Arthritis</a>
            <a href="#" class="nav-mega-link " itemprop="name" id="sec-menu2">Mission for<br>movement</a>
            <a href="#" class="nav-mega-link " itemprop="name" id="sec-menu2">Resources</a>
            <a href="#" class="nav-mega-link " itemprop="name" id="sec-menu2">Contact Us</a>
            <a href="#" class="nav-mega-link " itemprop="name" id="sec-menu2">Prescribing<br>Information</a>
    </nav>
</div>

<div class="text--block footerGroup">
<p class="cos-abv">ACR, American College of Rheumatology; AS, ankylosing spondylitis; ASAS, Assessment of SpondyloArthritis International Society; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; DMARDs, disease-modifying anti-rheumatic drugs; IL: interleukin; NASS: National Ankylosing Spondylitis Society; NSAID, non-steroidal anti-inflammatory drug; PASI, Psoriasis Area and Severity Index; PDE, phosphodiesterase; PsA, psoriatic arthritis; PsARC, Psoriatic Arthritis Response Criteria; SpA, spondyloarthritis; TNF, tumour necrosis factor; VAS, visual analogue scale</p>
<p class="cos-references"><strong>References</strong><br /><strong>1.</strong> Lee S <em>et al. P T</em> 2010; 35:680–689. <strong>2.</strong> Bond SJ <em>et al. Ann Rheum Dis</em> 2007; 66:370–376. <strong>3.</strong> McHugh NJ <em>et al. Rheumatology (Oxford)</em> 2003; 42:778–783. <strong>4.</strong> Haroon M <em>et al. Ann Rheum Dis</em> 2015; 74:1045–1050. <strong>5.</strong> Keat A<em> et al. Rheumatology</em> 2011; 50:1936–1939. <strong>6.</strong> Bakland G <em>et al. Ann Rheum Dis</em> 2011; 70:1921–1925. <strong>7.</strong> NICE. Managing spondyloarthritis in adults. January 2018. Available at: pathways.nice.org.uk/pathways/spondyloarthritis [accessed July 2018].<strong> 8.</strong> Cosentyx Summary of Product Characteristics, 2018.<strong> 9.</strong> Schett G <em>et al. Arthritis Res Ther</em> 2011; 13:S4. <strong>10.</strong> Lories RJ, McInnes IB. <em>Nat Med</em> 2012; 18:1018–1019. <strong>11.</strong> Østergaard M, Lambert RGW. <em>Ther Adv Musculoskel Dis</em> 2012; 4:301–311. <strong>12.</strong> Martindale J <em>et al. Best Pract Res Clin Rheumatol</em> 2015; 29:512–523. <strong>13.</strong> Kotsis K <em>et al. Expert Rev Pharmacoecon Outcomes Res</em> 2014; 14:857–872. <strong>14.</strong> Husni ME <em>et al. Semin Arthritis Rheum</em> 2017; 47:351–360. <strong>15.</strong> Durmus D <em>et al. Compr Psychiatry</em> 2015; 62:170–177. <strong>16.</strong> Derakhshan MH<em> et al. Rheumatology (Oxford)</em> 2018; 57:987–996. <strong>17.</strong> Novartis PsA Market Research. <strong>18.</strong> Sieper J <em>et al. Ann Rheum Dis</em> 2017; 76:571–575. <strong>19.</strong> Marzo-Ortega H <em>et al. EULAR</em> 2018; SAT0283.<strong> 20.</strong> Rheumatology DOF UK 154. <strong>21.</strong> Mease P, McInnes IB. Rheumatol Ther 2016; 3:5–29. <strong>22.</strong> Rheumatology DOF UK 1. 23. Rheumatology DOF UK 102. <strong>24.</strong> McInnes IB <em>et al. Rheumatology</em> 2017; 56:1993–2003.<strong> 25.</strong> Rheumatology DOF UK 108.</p>
</div>